SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation today announced that China’s Rujin Hospital in Shanghai has used the company’s integrated fluidic circuits (IFCs) to help validate two new susceptibility loci for Graves’ disease. Researchers applied the unique properties of the Fluidigm 96.96 Dynamic Array™ IFC and the EP1™ System to re-genotype selected SNPs for the replication study.
